Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.740 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about LAVA Therapeutics N.V. - Ordinary Shares

< Previous 1 2 Next >
News headline image
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Announces Appointment of New Directors to the Board
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board 
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts 
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223
LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development 
Via Spotlight Growth
News headline image
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
From Seagen Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.